GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (LTS:0AAJ) » Definitions » ROIC %

PolyPeptide Group AG (LTS:0AAJ) ROIC % : -4.28% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. PolyPeptide Group AG's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2024 was -4.28%.

As of today (2024-12-12), PolyPeptide Group AG's WACC % is 13.74%. PolyPeptide Group AG's ROIC % is -2.41% (calculated using TTM income statement data). PolyPeptide Group AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.


PolyPeptide Group AG ROIC % Historical Data

The historical data trend for PolyPeptide Group AG's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG ROIC % Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial 10.91 12.76 13.48 2.77 -6.23

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 5.42 -0.55 -11.52 -0.66 -4.28

Competitive Comparison of PolyPeptide Group AG's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPeptide Group AG's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's ROIC % distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's ROIC % falls into.



PolyPeptide Group AG ROIC % Calculation

PolyPeptide Group AG's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-34.392 * ( 1 - 11.68% )/( (481.065 + 493.391)/ 2 )
=-30.3750144/487.228
=-6.23 %

where

PolyPeptide Group AG's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2024 is calculated as:

ROIC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-24.19 * ( 1 - 7.51% )/( (493.391 + 552.932)/ 2 )
=-22.373331/523.1615
=-4.28 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=639.775 - 40.205 - ( 46.638 - max(0, 176.652 - 281.555+46.638))
=552.932

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PolyPeptide Group AG  (LTS:0AAJ) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, PolyPeptide Group AG's WACC % is 13.74%. PolyPeptide Group AG's ROIC % is -2.41% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


PolyPeptide Group AG ROIC % Related Terms

Thank you for viewing the detailed overview of PolyPeptide Group AG's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


PolyPeptide Group AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.

PolyPeptide Group AG Headlines

No Headlines